英国制药企业葛兰素史克（GSK）已了结相关诉讼，这些诉讼指控莫德纳的新冠疫苗Spikevax、mNEXSPIKE以及呼吸道合胞病毒（RSV）疫苗mResvia侵犯了GSK的专利。两家公司周五表示。
British drugmaker GSK has settled lawsuits that accused Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, the companies said on Friday.
作者：布莱克·布里顿。莫德纳在周五的新闻稿中表示，公司已于10月28日了结GSK在美国和欧洲的专利诉讼，两家公司“在传染病领域相互授予专利交叉许可，且无需就该等许可支付任何款项”。
By Blake Brittain Moderna said in a Friday press release that it settled GSK's patent litigation in the US and Europe on October 28 and that the companies "granted patent cross-licenses in the field of infectious disease and are not obligated to make payments of any kind in connection with such licenses."
GSK的一名发言人表示，公司“很高兴达成了一项解决方案，为双方提供了明确性，并使双方能够继续专注于推进为患者带来创新”。
A GSK spokesperson said the company was "pleased to have reached a resolution that provides clarity for both companies and enables continued focus on advancing innovation for patients."
两家公司周五请求特拉华州联邦法院以不得再诉的方式驳回GSK在美国的侵权主张，这意味着这些主张不能再次提起。GSK于2024年起诉莫德纳，涉及疫苗中用于将脆弱的信使RNA（mRNA）运送进人体的脂质纳米颗粒技术。同年早些时候，GSK还就其新冠疫苗另行对辉瑞和BioNTech提起了类似诉讼，该案目前仍在进行中。这些诉讼是辉瑞、BioNTech和莫德纳之间围绕其新冠疫苗所用技术专利许可费的一系列美国法院案件的一部分，其中包括莫德纳于2022年对辉瑞提起的诉讼。
The companies asked a Delaware federal court on Friday to dismiss GSK's US infringement claims with prejudice, which means they cannot be refiled GSK sued Moderna in 2024 over lipid nanoparticle technology used in the vaccines to transport fragile messenger RNA (mRNA) into the human body GSK separately filed a similar lawsuit against Pfizer and BioNTech over their COVID-19 vaccine earlier that year, which is still ongoing The lawsuits are part of a web of US court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their COVID vaccines, including one brought by Moderna against Pfizer in 2022